Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ExposureDefinition: Therapeutic-dose anticoagulation with heparin - JSON Representation

Raw json | Download

{
  "resourceType" : "Group",
  "id" : "179786",
  "meta" : {
    "versionId" : "3",
    "lastUpdated" : "2023-12-04T20:30:40.963Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"
    ]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 179786</b></p><a name=\"179786\"> </a><a name=\"hc179786\"> </a><a name=\"179786-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 3; Last updated: 2023-12-04 20:30:40+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-exposure-definition.html\">ExposureDefinition</a></p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786.)</p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/179786\">https://fevir.net/resources/Group/179786</a></p><p><b>identifier</b>: FEvIR Object Identifier/179786</p><p><b>name</b>: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin</p><p><b>title</b>: ExposureDefinition: Therapeutic-dose anticoagulation with heparin</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Description: therapeutic-dose anticoagulation with heparin\nNote: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.</p>\n</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: Any of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Defined by CodeableConcept</span></p><p><b>value</b>: <span title=\"Codes:\">Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>ATTACC investigational arm</p>\n</div><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen&gt;24 hours, provided oxygen was required), whichever comes first.</td></tr></table></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Defined by CodeableConcept</span></p><p><b>value</b>: <span title=\"Codes:\">Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>ACTIV-4a investigational arm</p>\n</div><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge, whichever comes first.</td></tr></table></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Defined by CodeableConcept</span></p><p><b>value</b>: <span title=\"Codes:\">Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>REMAP-CAP investigational arm</p>\n</div><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge, whichever comes first.</td></tr></table></blockquote></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
      "valueRelatedArtifact" : {
        "type" : "cite-as",
        "citation" : "ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786."
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail" : {
        "name" : "Brian S. Alper"
      }
    }
  ],
  "url" : "https://fevir.net/resources/Group/179786",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net",
      "value" : "179786",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "name" : "ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin",
  "title" : "ExposureDefinition: Therapeutic-dose anticoagulation with heparin",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description" : "Description: therapeutic-dose anticoagulation with heparin\nNote: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.",
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "membership" : "conceptual",
  "combinationMethod" : "any-of",
  "characteristic" : [
    {
      "code" : {
        "text" : "Defined by CodeableConcept"
      },
      "valueCodeableConcept" : {
        "text" : "Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."
      },
      "exclude" : false,
      "description" : "ATTACC investigational arm",
      "timing" : [
        {
          "contextCode" : {
            "text" : "Start of trial"
          },
          "offsetRange" : {
            "low" : {
              "value" : 0
            },
            "high" : {
              "value" : 14,
              "unit" : "days",
              "system" : "http://unitsofmeasure.org",
              "code" : "d"
            }
          },
          "text" : "Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen>24 hours, provided oxygen was required), whichever comes first."
        }
      ]
    },
    {
      "code" : {
        "text" : "Defined by CodeableConcept"
      },
      "valueCodeableConcept" : {
        "text" : "Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal."
      },
      "exclude" : false,
      "description" : "ACTIV-4a investigational arm",
      "timing" : [
        {
          "contextCode" : {
            "text" : "Start of trial"
          },
          "offsetRange" : {
            "low" : {
              "value" : 0
            },
            "high" : {
              "value" : 14,
              "unit" : "days",
              "system" : "http://unitsofmeasure.org",
              "code" : "d"
            }
          },
          "text" : "Up to 14 days or until hospital discharge, whichever comes first."
        }
      ]
    },
    {
      "code" : {
        "text" : "Defined by CodeableConcept"
      },
      "valueCodeableConcept" : {
        "text" : "Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."
      },
      "exclude" : false,
      "description" : "REMAP-CAP investigational arm",
      "timing" : [
        {
          "contextCode" : {
            "text" : "Start of trial"
          },
          "offsetRange" : {
            "low" : {
              "value" : 0
            },
            "high" : {
              "value" : 14,
              "unit" : "days",
              "system" : "http://unitsofmeasure.org",
              "code" : "d"
            }
          },
          "text" : "Up to 14 days or until hospital discharge, whichever comes first."
        }
      ]
    }
  ]
}